Breaking News

Hovione to Expand New Jersey Facility

Site will offer drug substance, spray drying, hot melt extrusion and drug product manufacturing services

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hovione has unveiled plans for the expansion of its East Windsor, NJ facility. The expansion will add an additional 30,600 square feet to the existing 24,000 square feet facility. It will introduce a new commercial spray dryer unit to complement the existing pilot unit and this installation will be specifically designed to handle potent drug substances (APIs). In addition the Hovione NJ facility will more than double its capacity to manufacture drug substance. The expansion is expected to add approximately 60 new jobs to the current workforce over the next three years.

“The start of the construction activities to expand our site in East Windsor is a very exciting moment for us and for our customers,” said Marco Gil, general manager, Hovione New Jersey. “This is an important step to strengthen our continued commitment to the pharmaceutical industry and to the patients by offering innovative technologies and services.

The company said the site will be unique in offering at a single location drug substance, spray drying, hot melt extrusion and drug product manufacturing services using innovative continuous manufacturing technology.

“This investment is part of the company’s strategy to increase its global development and commercial capacity which will meet the increasing demands of Hovione’s customers in the API and Spray drying services,” said Kristine Senft, vice president marketing and sales, Hovione. “It will also include the addition of a continuous drug product manufacturing capability to its offering through the partnership with Vertex Pharmaceuticals announced earlier this year.”


The start-up of the operation is expected to take place in April 2017 for the drug substance and spray drying services while the continuous drug product manufacturing is planned for the end of 2017.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters